SYRA Syra Health Corp

Overview and Growth

Fiscal 2025 results for Syra Health Corp combined $7.23M of revenue with net loss of $896.33K and an operating cash outflow of $447.75K. Revenue of $7.23M sets the scale for evaluating how effectively sales translated into profit and cash during the year. Compared with $7.98M in fiscal 2024, revenue decreased 9.5%, a top-line contraction that reduced operating scale. The company reported diluted EPS of -$0.08, adding a shareholder-level measure to the absolute income figures considered below. A diluted share base of 11.85M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. Compared with 7.55M diluted shares in fiscal 2024, the current 11.85M base was 57.0% higher. At period end, total assets were $2.77M, framing the scale of the company’s operating and financing commitments. The revenue-to-assets relationship was 2.61x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

Gross profit was $2.49M, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. Gross profit represented 34.4% of revenue, showing how much of the top line remained after direct costs. Operations produced a $904.32K operating loss before non-operating and tax effects. An operating margin of -12.5% reflected costs exceeding revenue-level gross profit by 12.5% of sales. After all below-operating-line items, the company recorded a net loss of $896.33K for the fiscal year. Measured against revenue, the bottom-line deficit represented 12.4% after all recognized items. Negative EBITDA totaled $883.86K, confirming that the earnings deficit remained before depreciation and amortization. The net loss equaled 42.7% of period-end equity, showing the deficit relative to book capital. The loss-to-assets relationship was 32.3%, placing the bottom-line deficit against the company’s resource base. Compared with a $3.76M net loss in fiscal 2024, the current loss improved to $896.33K.

Liquidity and Capital Structure

The company held $2.77M of assets against $674.74K of liabilities and $2.10M of equity, revealing how the asset base was financed. Current assets were $2.74M against $674.74K of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. At 4.06x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Cash and equivalents totaled $1.61M, identifying the most liquid reported component available within the broader current-asset balance. Measured only with cash and equivalents, coverage of current liabilities was 239.3%, excluding receivables and other current assets. Book equity represented 75.7% of total assets, quantifying the balance-sheet share supported by shareholder capital. Liabilities represented 24.3% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 58.2% of total assets, showing the liquid cash component within the company’s broader resource base. The asset base changed 24.6% from $3.68M in fiscal 2024, leaving current total assets lower year over year. Reported equity changed 27.1% from $2.88M in fiscal 2024, placing the current capital base lower year over year. Compared with $2.40M in fiscal 2024, the current cash balance moved 32.6% and finished lower.

Cash Flow and Earnings Quality

Operating activities used $447.75K of cash, resulting in an operating cash outflow for the year. Capital spending of $107.00 added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. Negative free cash flow was $447.85K, leaving a cash deficit after capital spending and reducing financial flexibility. The free-cash-flow deficit equaled 6.2% of revenue, showing the post-investment cash shortfall relative to sales. The cash deficit after capital spending represented 16.2% of the period-end asset base. The operating cash outflow narrowed to $447.75K from $2.93M in fiscal 2024.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.